Drug Discovery Today
APRIL 14, 2023
Through a series of exclusive interviews and a survey of industry insiders, Connect in Pharma names the top pharmaceutical and manufacturing-related trends of 2023
Antidote
APRIL 12, 2023
Every April is National Minority Health Month , organized by the U.S. Department of Health and Human Services. This month is intended to highlight the focus on improving the health of racial and ethnic minorities by reducing health disparities and increasing equal access to care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
APRIL 12, 2023
In Drug Channels Institute’s list of the top 15 pharmacies of 2022 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. To complement that broader ranking, we rummaged around our DreamHouse to update our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues in 2022.
Drug Patent Watch
APRIL 13, 2023
Annual Drug Patent Expirations for ZOSYN+IN+PLASTIC+CONTAINER Zosyn In Plastic Container is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers. There… The post New patent expiration for Wyeth Pharms drug ZOSYN IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
NIOSH Science Blog: Drugs
APRIL 12, 2023
In November 2022, the American Journal of Industrial Medicine (AJIM) published a special issue focusing on work-related fatigue. The issue explores factors that may increase work-related fatigue and actions to reduce work-related injuries and illnesses. [1] This issue is a result of discussions and collaborations from the 2019 NIOSH Working Hours, Sleep and Fatigue Forum and also pulls from reports by the National Institute for Occupational Safety and Health (NIOSH) on long work hours and shift
FDA Law Blog: Biosimilars
APRIL 13, 2023
By Larry K. Houck — Eric Idle, as a body collector, immortalized the phrase, “Bring out your dead,” in the 1975 comedy classic, Monty Python and the Holy Grail. The Drug Enforcement Administration (“DEA”) could voice a modern variation, “Bring out your meds,” as the agency and its law enforcement partners host local drop-off locations nationwide for safe disposal of unneeded medication on Saturday, April 22, 2023, from 10:00 a.m. to 2:00 p.m. local time.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Covalent Modifiers
APRIL 14, 2023
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, and Takeshi Sagara ACS Medicinal Chemistry Letters 2023 14 (4), 396-404 DOI: 10.1021/acsmedchemlett.3c00006 Deregulating fibroblast growth factor receptor (FGFR) signaling is a promising strategy for cancer therapy.
NIOSH Science Blog: Drugs
APRIL 10, 2023
As a critical part of their job, firefighters often climb aerial ladders up to 30 meters (or 98 feet) long and positioned at various angles. Aerial ladders are mechanically-operated, long, extendable ladders mounted on fire trucks and are used to reach high places for extinguishing fires and rescue operations. While climbing, firefighters typically wear heavy protective equipment and may also carry additional equipment related to fighting fires or rescuing occupants from burning buildings.
FDA Law Blog: Biosimilars
APRIL 10, 2023
By Larry K. Houck — Drugs and substances classified within schedule I of the federal Controlled Substances Act (“CSA”) by definition have a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision. 21 U.S.C. § 812(b)(1). Last month bipartisan legislation, S. 689 and H. 1393 introduced in the Senate and the House, would facilitate removing barriers to research and compassionate use for schedule I co
Drug Patent Watch
APRIL 14, 2023
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs… The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Cytel
APRIL 14, 2023
Real-world data and evidence are increasingly being used in health care decisions and publications. However, there are challenges in identifying suitable data for external control arms, and researchers need to consider solutions to address issues like data quality, bias, and selection bias when using real-world evidence for comparative efficacy analyses.
LifeSciVC
APRIL 14, 2023
Times remain tough for private biotech venture capital funding. Access to capital is more constrained than it’s been in years, and companies are starting to feel the pinch. Yet, despite the pain after a cycle of excess, perhaps this return towards more discipline should be embraced. As has already been widely reported , aggregate venture capital funding in the first quarter of 2023 is well off its peaks of 2020-2022.
PLOS: DNA Science
APRIL 13, 2023
Drug addiction is prevalent and deadly. In the US in 2021, more than 46 million people aged 12 or older had addiction to at least one substance, yet only 6.3% received treatment, according to the National Institute on Drug Abuse (NIDA). A complex mix of gene variants and environmental factors lies behind the compulsion to repeatedly take a drug and increase the dose, despite knowing the dangers.
Drug Patent Watch
APRIL 14, 2023
Annual Drug Patent Expirations for PRESTALIA Prestalia is a drug marketed by Adhera and is included in one NDA. There are two patents protecting this drug and one Paragraph IV… The post New patent expiration for Adhera drug PRESTALIA appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
FDA Law Blog: Biosimilars
APRIL 12, 2023
On Thursday, April 20, from 1:30-3:00pm, John Claud of Hyman, Phelps & McNamara, P.C. will present a webinar entitled “ Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC.” John will provide participants with a greater understanding of new guidance implications, as well as recent guidance on delaying, denying, limiting, or refusing an inspection, and the DOJ’s revised Corporate Enforcement Policy, which altered the way the agency reviews corporate criminal prosecution
Drug Target Review
APRIL 12, 2023
Artificial intelligence (AI) AI has seen quite a boom in the last couple of years, overcoming challenges such as limited and low-quality data. Researchers can avoid numerous delays by employing AI for drug discovery, often using computational approaches in combination with their own techniques, for a faster and smoother path to the clinic. 1 Getting to grips with what AI can do and how best to acquire and utilise its skills.
Crown Bioscience
APRIL 12, 2023
The development of new drugs and biological products has traditionally mandated animal testing, but the FDA Modernization Act 2.0 allows for alternative non-clinical testing, allowing reliable alternatives for drug discovery and biological product applications.
Drug Patent Watch
APRIL 14, 2023
Annual Drug Patent Expirations for EYSUVIS Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Alcon Labs drug EYSUVIS appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Crucial Data Solutions
APRIL 11, 2023
RENO, Nev.–(BUSINESS WIRE)–Crucial Data Solutions (CDS), a provider of innovative technologies to advance clinical research, announced today that industry veteran. The post Jim Bob Ward Appointed as Chief Strategy Officer at eClinical Provider Crucial Data Solutions appeared first on Crucial Data Solutions.
Cytel
APRIL 11, 2023
Commonly used methods to handle the complexities of effect modification in indirect treatment comparisons (ITCs) often rely on the shared effect modifier (SEM) assumption, that is, that the effect modifiers impact a set of treatments in the evidence network in the same way. However, it has been argued that this assumption is limiting and often unreasonable to make.
Crown Bioscience
APRIL 12, 2023
Although radiotherapy (also called radiation therapy ) is an important aspect of cancer treatment, it has limitations, including its potential for damaging healthy tissues, induction of radiotherapy resistance, requiring well-oxygenated tumors, and potentially increasing the risk for generating metastases. There remains an unmet need for ways to enhance radiotherapy.
Drug Patent Watch
APRIL 14, 2023
Annual Drug Patent Expirations for PHENYLEPHRINE+HYDROCHLORIDE Phenylephrine Hydrochloride is a drug marketed by Akorn, Mankind Pharma, Paragon Bioteck, Accord Hlthcare, Amneal, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd,… The post New patent for HIKMA drug PHENYLEPHRINE HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.
ACTO
APRIL 11, 2023
An insightful piece from the Life Sciences Trainers & Educators Network (LTEN) focusing on Building the Right Learning Technology Architecture sparked a conversation at ACTO about determining the value that your learning technology stack delivers and the importance of defining that correctly. In the LTEN article, Rich Baron aptly stated, “It’s not about which technology is best.
Advarra
APRIL 11, 2023
Effective participant recruitment is crucial to a successful clinical trial, but recruiting eligible participants in sufficient numbers has long been a challenge. As trials become more complex, and calls for appropriate diversity in participant populations increase, the problem is intensifying. Smaller sites often have the most difficulty, and fewer resources for meeting the challenges.
Antidote
APRIL 11, 2023
Asthma is a condition that can impact anyone — and currently, it affects over 26.5 million people in the United States. In spite of available treatments, asthma is responsible for 1.3 million emergency room visits and over 3,500 deaths every year. Additionally, asthma’s impact is not evenly distributed; the condition impacts a disproportionate number of women, children, and minority populations, and has a direct correlation with an individual’s socioeconomic status.
Drug Patent Watch
APRIL 13, 2023
Annual Drug Patent Expirations for ZOSYN Zosyn is a drug marketed by Wyeth Pharms and is included in two NDAs. There are three patents protecting this drug and two Paragraph… The post New patent expiration for Wyeth Pharms drug ZOSYN appeared first on DrugPatentWatch - Make Better Decisions.
National Institute on Drug Abuse: Nora's Blog
APRIL 10, 2023
Is It Too Soon To Start Talking about a Cure for Addiction? mfleming Mon, 04/10/2023 - 14:43 Nora's Blog April 13, 2023 Image Getty Images/ AleksandarGeorgiev This article originally appeared in the Milken Institute’s Power of Ideas series. Our country remains in the grips of an opioid crisis claiming more than 100,000 lives every year. Rising mortality associated with drug addiction and excessive drinking is among the major factors contributing to declining life expectancy.
Codon
APRIL 9, 2023
This is Codon Digest, my weekly roundup of research, news, and industry highlights about the future of biology. Also: I’ve turned on paid subscriptions. No plans for exclusive content just yet, but if you’d like to support my work for $3 or $5 per month, please consider it. My goal is to reach 100 supporters! Thank you for being here. Support Codon for $3 per month.
Zobio
APRIL 13, 2023
In person From 10 to 13 June Michael Nyman attended ACSMEDI-EFMC Medicinal Chemistry Frontiers symposium in Boston. The conference was co-organized as a collaboration between the ACS (American Chemical Society), MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal Chemistry and Chemical Biology). The meeting attracted a highly targeted audience composed of experts, researchers and.
Drug Patent Watch
APRIL 13, 2023
Annual Drug Patent Expirations for EDURANT Edurant is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are four patents… The post New patent expiration for Janssen Prods drug EDURANT appeared first on DrugPatentWatch - Make Better Decisions.
Elrig
APRIL 13, 2023
Driving sustainability in drug discovery: A community approach Driving sustainability in drug discovery: A community approach Author: Sanj Kumar, CEO, ELRIG UK The pharma and biotech industry is growing. While this brings the promise of new therapeutics for currently untreatable diseases, the increasing environmental impact of the industry cannot be ignored.
The Pharma Data
APRIL 12, 2023
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).
Zobio
APRIL 13, 2023
In person From 10 to 13 June Michael Nyman attended ACSMEDI-EFMC Medicinal Chemistry Frontiers symposium in Boston. The conference was co-organized as a collaboration between the ACS (American Chemical Society), MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal Chemistry and Chemical Biology). The meeting attracted a highly targeted audience composed of experts, researchers and.
Expert insights. Personalized for you.
113 
Let's personalize your content